Needham Reiterates Buy on Artiva Biotherapeutics, Maintains $41 Price Target
Benzinga Newsdesk 4 months ago
NewsPrice TargetReiterationAnalyst Ratings
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.
Needham analyst Gil Blum reiterates Artiva Biotherapeutics (NASDAQ:ARTV) with a Buy and maintains $41 price target.